Past issues are only available to subscribers. If you are not a member, click here to join.

Issue 22 - May. 31, 2019
Issue 21 - May. 24, 2019
  • Trials & Tribulations

    Why I choose to play a dual role in TMIST

    As a physician-scientist, I have spent my career advancing research in women’s health. I was a part of the planning effort to design and launch TMIST—the Tomosynthesis Mammographic Imaging Screening Trial.

  • Dana-Farber wins legal dispute over PD-1/PD-L1 patents; BMS set to lose exclusive license

    So, you’ve finished your copy of the Mueller Report and you long for another great read from the same publisher—the U.S. government.

  • Review

    Chernobyl, the HBO miniseries: Fact and fiction (Part II)

    Last week, I discussed events resulting in the Chernobyl NPF accident, including unique aspects of the reactor-design which contributed to the accident, and which resulted in release of radiation to the environment. I also discussed the initial Soviet response. Next, I focus on the immediate medical consequences and the response of Soviet government to medical interventions.

  • In Brief

    • Mullighan named deputy director of St. Jude
    • Dimopoulos and Mateos to receive achievement awards from IMF
    • Singh named sub-PI Heartland Cancer Research NCORP Executive Committee
    • Douglas Lowy receives NYU honorary degree
  • Funding Opportunities

    Astellas Oncology calls for entries to C3 Prize to award $200,000

    Astellas Pharma Inc. is calling for entries for the fourth annual Astellas Oncology C3 Prize (Changing Cancer Care), a challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones.

  • TCCL Logo

  • Clinical Roundup

    • UPenn study shows adding bevacizumab improves OS in NSCLC
    • NRG Oncology phase III study results: partial breast irradiation is effective
    • First states to expand Medicaid saw larger screening rate increases
  • Drugs & Targets

    • Oncopeptides to submit NDA for melflufen in multiple myeloma
Issue 20 - May. 17, 2019
  • Conversation with The Cancer Letter

    Libutti: How Rutgers Cancer Institute became a New Jersey-sized colossus

     When NCI renewed the Comprehensive Cancer Center designation for Rutgers Cancer Institute of New Jersey, it also acknowledged that the institution’s catchment area now covers the entire state of New Jersey, having expanded from roughly three counties around its home location of New Brunswick.

  • ODAC votes down AML drug as FDA raises concerns over equipoise, uncertain efficacy

    The FDA Oncologic Drugs Advisory Committee May 14 voted 8-3 against approval of quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia which is FLT3- ITD positive, as detected by an FDA-approved test.

  • Texas Senate approves $3 billion measure to renew CPRIT funding

    The Texas Senate May 10 passed a measure that would provide new funding for the Cancer Prevention and Research Institute of Texas.

  • Review

    Chernobyl, the HBO miniseries: Fact and fiction

    Two weeks ago, HBO began screening a five-part series on Monday nights on the Chernobyl nuclear power facility (NPF) accident, which occurred more than 30 years ago on April 26, 1986.

  • In Brief

    • Hollings Cancer Center receives NCI-designation renewal
    • Bold named physician-in-chief of UC Davis Comprehensive Cancer Center
    • Endowed gift establishes Dr. Cyrus Katzen Family Director at GW Cancer Center
    • Borghaei, Clapper, Golemis, Wasik, Whetstine receive endowed chairs at Fox Chase
    • UAMS Cancer Institute BMT program receives internationally recognized accreditation
    • ACS CAN report shows short-term insurance coverage is inadequate, confusing and expensive for patients
    • ACS sets goal to reduce overall cancer mortality 40% by 2035
    • COA launches campaign to stop “PBM Abuses”
    • Hungary joins International Agency for Research on Cancer
  • TCCL Logo

  • Clinical Roundup

    • ASCO announces top studies to be presented at 2019 annual meeting
    • Tibsovo achieved primary endpoint in cholangiocarcinoma
    • Earlier, more frequent removal of some pancreatic cysts may decrease cancer risk
  • Drugs & Targets

    • FDA approves Venclexta in chronic lymphocytic leukemia
    • FDA approves ramucirumab in hepatocellular carcinoma
    • FDA approves Bavencio + Inlyta combination in renal cell carcinoma
    • GE Healthcare and Indi Molecular partner on diagnostic tool for immunotherapy patients